Latest Posts

27

Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

German Blockchain, AI Platform to ‘Democratize’ Drug Development

Germany-based company Innoplexus AG said that iPlexus (one of its subsidiaries) will leverage blockchain technology and AI to resolve inefficiencies in early-stage drug discovery.

The company also has its offices in Pune, India and Hoboken in the United States of America.

The subsidiary will give researchers a secure, blockchain-and-AI-based platform for publishing and extending license to use unpublished data from successful and failed experiments. IP will be secured on the blockchain with an immutable timestamp, and AI will analyze all uploaded data to determine its value for ongoing drug development research.

The company in a statement said, all the unpublished data will also be available alongside the published data.

The Chief Executive Officer (CEO) and co-founder Gunjan Bhardwaj said, “Our mission at Innoplexus is to democratize the drug discovery process. We believe that cutting-edge technologies like AI and blockchain are the key to making this possible. After over 6 months of research, we believe that the new iPlexus is a major step forward for the preclinical trial industry and will solve many of the problems that are slowing the industry down. By overcoming these challenges, we will make drug discovery more efficient and bring down the consumer price of drugs.”

This technology update came soon on the heels of a recent study conducted by the company which said consumer perceptions of the pharma industry continue to be negative, with only 20% of consumers reporting a positive view of pharmaceutical companies. However, 64% said that their opinion of the industry would improve if drug prices were reduced.

The original article was published on Crypto News.

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…